Switzerland-based pharma giant Roche has agreed to acquire Flatiron Health for $2.1 billion.
Roche, a significant investor in Flatiron, will pay $1.9 billion to combine with its existing stake for the total deal value.
Flatiron is a startup which owns an electronic medical record system used by doctors in the field of oncology. It uses this data to determine more effective ways to treat cancer.
The transaction is expected to close in the first half of 2018.
Flatiron Health was founded by Nat Turner and Zach Weinberg, both former Google employees. Alphabet’s venture arm GV holds a large stake in Flatiron, alongside Roche.
This makes you wonder if Alphabet has truly lost a golden goose by giving away Flatiron.
In 2016, Flatiron had announced plans to go public in two to three years. That year, Roche led a $175-million deal in Flatiron valuing it at $1.2 billion. Roche had also agreed to buy several of Flatiron’s subscription-based software products, which would position the company for an IPO.
Flatiron CEO Nat Turner stated that Flatiron would remain an independent legal entity within the Roche group. The employees will continue as Flatiron employees.
Flatiron has raised more than $300 million from various investors in technology and healthcare.
Most Popular
Important takeaways from Paychex’s (PAYX) Q2 2025 earnings report
Paychex Inc. (NASDAQ: PAYX), a leading provider of human resources and payroll services, reported better-than-expected revenue and profit for the second quarter of fiscal 2025, sending the stock higher soon
Lamb Weston’s (LW) challenges may not end soon, a few points to note
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) turned red in mid-day trade on Friday. The stock has dropped 19% in the past one month. The company delivered disappointing results
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss